Back to search

Article

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma

2023-08-09

Abstract excerpt

<h4>Purpose: </h4> The intravenous administration (IV) of daratumumab sometimes causes an infusion reaction and needs a long infusion time. Recently, a subcutaneous formulation (SC) of daratumumab, which has fewer infusion reactions and shorter administration time, was approved. However, because SC has a fixed dose, overdosing is a concern for patients with low body weights. In this study, we investigated the safe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
622ed1dc-0692-521a-80f1-3b91822b00e5
DOI
10.21203/rs.3.rs-3229878/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myelomaDOI 10.21203/rs.3.rs-3229878/v1
Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapySemantic proximity
The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity
INCIDENCE AND ASSOCIATED FACTORS WITH THE CHANGE FREE TIME BETWEEN THE BRANDED OR GENERIC IMATINIB IN NAIVE PATIENTS WITH CHRONIC MYELOID LEUKEMIASemantic proximity
Optimal control of Multiple Myeloma assuming drug evasion and off-target effectsSemantic proximity
Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection.Semantic proximity
Clinical significance on Switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancerSemantic proximity
Safety of rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin’s Lymphoma: A Retrospective StudySemantic proximity
Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.Semantic proximity
Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: an observational study in rheumatoid arthritis patientsSemantic proximity
Comparative real-world retention rate and safety of Biosimilar IBI303 versus Humira in Ankylosing SpondylitisSemantic proximity
Busulfan pharmacokinetics in adults – a real-world evaluation of intra-individual variabil-ity and the impact of obesity and deferasiroxSemantic proximity
Select a neighboring publication to make it the new centre.